

In the Claims:

1. (currently amended) A film-shaped, mucoadhesive administration form containing a cannabis agent selected from the group consisting of cannabis extract [[or a]] and cannabis oil.
2. (previously presented) The administration form according to claim 1, wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties.
3. (currently amended) The administration form according to claim 2, wherein said polymer matrix contains at least one polymer being water-soluble and/or swellable in an aqueous media, said polymers at least one polymer is selected from the group consisting of starch and starch derivatives, dextran, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or propyl cellulose, polyacrylic acid, polyacrylates, polyvinyl pyrrolidones, polyethylene oxide polymers, polyacrylamides, polyethylene glycol, gelatine, collagen, alginates, pectins, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar-agar, agarose, carrageenan and natural gums, and wherein said administration form comprises said at least one polymer at a portion of 5 to 95%-wt.
4. (currently amended) The administration form according to claim 1, wherein said administration form contains said cannabis agent selected from the group consisting of [[the]] cannabis extract [[or the]] and cannabis oil in an amount of 0.5 to 50%-wt.
5. (previously presented) The administration form according to claim 1, wherein said administration form further contains at least one substance selected from the group consisting of flavourings, odorous substances and aromatics.
6. (previously presented) The administration form according to claim 1, wherein the layer thickness is 0.01 to 2 mm.
7. (previously presented) The administration form according to claim 1, wherein said administration form further contains at least one inactive ingredient selected from the group consisting of fillers, colourants, emulsifiers, plasticizers, sweeteners, preservatives, pH regulators, permeation-enhancing substances, and antioxidants.
8. (previously presented) The administration form according to claim 1, wherein said administration form has a multilayer structure with at least one layer having an active agent content.
9. (currently amended) ~~Use of a cannabis extract or of a cannabis oil for the~~

~~production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of:~~ A method of treating conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea, said method comprising the step of:

administering a film-shaped, mucoadhesive administration form containing a cannabis agent selected from the group consisting of cannabis extract and cannabis oil to an afflicted person.

10. (currently amended) ~~Use of a cannabinoid active agent, selected from the group consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen, for the production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of:~~ A method of treating conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea, said method comprising the step of:

administering a film-shaped, mucoadhesive administration form to an afflicted person, said administration form containing a cannabinoid active agent selected from the group of active agents consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen.

11. (currently amended) ~~The use~~ The method according to claim 9, wherein the

administration form is ~~[[an]]~~ a film-shaped, mucoadhesive administration form according to claim 2 containing a cannabis agent selected from the group consisting of cannabis extract and cannabis oil, and wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties.

12. (currently amended) ~~The use~~ The method according to claim 9, wherein the treatment is effected by application of the administration form to the oral mucosa.

13. (currently amended) ~~Use of an administration form according to claim 1 for therapeutic treatment, of:~~ A medicinal product for treating conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea, said medicinal product comprising a film-shaped, mucoadhesive administration form containing a cannabis agent selected from the group consisting of cannabis extract and cannabis oil.

14. (currently amended) ~~Use of a film-shaped, mucoadhesive administration form containing a cannaboid active agent, selected from the group consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen, for therapeutic treatment of:~~ A medicinal product for treating conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine;

dysmenorrhoea, said medicinal product comprising a film-shaped, mucoadhesive administration form containing a cannabinoid active agent selected from the group of active agents consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen.

15. (currently amended) ~~The use~~ The medicinal product according to claim 14, wherein the administration form is ~~[[an]]~~ a film-shaped, mucoadhesive administration form according to claim 2 containing a cannabis agent selected from the group consisting of cannabis extract and cannabis oil, and wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties, said reservoir containing said cannabis extract or cannabis oil.

16. (currently amended) ~~The use~~ The medicinal product according to claim 13, ~~wherein the application is carried out~~ wherein the administration form is an administration form for application on the oral mucosa.

17. (previously presented) The administration form according to claim 3, wherein said administration form comprises said polymer at a portion of 15 to 75%-wt.

18. (currently amended) The administration form according to claim 4, wherein said administration form contains ~~[[the]]~~ said cannabis agent selected from the group consisting of cannabis extract ~~[[or the]]~~ and cannabis oil in an amount of 1 to 30%-wt.

19. (currently amended) The administration form according to claim 5, wherein said flavourings, odorous substances and aromatics are selected from the group consisting of menthol, eucalyptol, limonene, phenyl ethanol, camphene, pinene, ~~seasoning aromatics~~ n-butyl phthalide, cineol, eucalyptus oil, thyme oil, methyl salicylate, turpentine oil, camomile oil, ethyl vanillin, 6-methyl coumarin, citronellol, and acetic acid n-butyl ester.

20. (canceled)

21. (previously presented) The administration form according to claim 6, wherein the layer thickness is 0.05 to 0.5 mm.

22. (currently amended) ~~The use~~ The method according claim 12, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application ~~[[or]]~~ and buccal application.

23. (currently amended) ~~The use~~ The method according to claim 10, wherein the administration form is ~~[[an]]~~ a film-shaped, mucoadhesive administration form according to claim 2 containing a cannabinoid agent selected from the group

consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromen and wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties.

24. (currently amended) ~~The use~~ The method according to claim 10, wherein the treatment is effected by application of the administration form to the oral mucosa.

25. (currently amended) ~~The use~~ The method according claim 24, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application ~~[[or]]~~ and buccal application.

26. (currently amended) ~~The use~~ The medicinal product according claim 16, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application ~~[[or]]~~ and buccal application.

27. (currently amended) ~~The use~~ The medicinal product according to claim 14, wherein ~~the application is carried out~~ the administration form is an administration form for application on the oral mucosa.

28. (currently amended) ~~The use~~ The medicinal product according claim 27, wherein the application of the administration form to the oral mucosa is selected from the group consisting of sublingual application ~~[[or]]~~ and buccal application.

29. (new) A film-shaped, mucoadhesive administration form containing a cannabis agent selected from the group consisting of cannabis extract and cannabis oil, wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties, wherein said administration form contains said cannabis agent selected from the group consisting of cannabis extract and cannabis oil in an amount of 0.5 to 50%-wt, and wherein the layer thickness is 0.01 to 2 mm.

30. (new) The administration form according to claim 29, wherein said polymer matrix contains at least one polymer being water-soluble and/or swellable in an aqueous media, said at least one polymer is selected from the group consisting of starch and starch derivatives, dextran, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or propyl cellulose, polyacrylic acid, polyacrylates, polyvinyl pyrrolidones, polyethylene oxide polymers, polyacrylamides, polyethylene glycol, gelatine, collagen, alginates, pectins, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar-agar, agarose, carrageenan and natural gums, and wherein said administration form comprises said at

least one polymer at a portion of 5 to 95%-wt.

31. (new) The administration form according to claim 30, wherein said administration form has a multilayer structure with at least one layer having an active agent content.

32. (new) The administration form according to claim 29, wherein the administration form is a film-shaped, mucoadhesive administration form containing a cannabinoid agent selected from the group consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen and wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties.

33. (new) The medicinal product according to claim 13, wherein said administration form comprises a polymer matrix, said polymer matrix being an active substance reservoir and having mucoadhesive properties, said reservoir containing said active agent selected from the group consisting of tetrahydrocannabinol, cannabinal, cannabidiol and cannabichromen.